Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-14 01:11 | 2026-01-12 | ZYME | Zymeworks Inc. | Hollywood Mark | Officer | OPT+S | $22.67 | 6,120 | $138,762 | 132,913 |
| 2026-01-14 00:36 | 2026-01-12 | LQDA | Liquidia Corp | Krepp Sarah | Officer | OPT+S | $37.43 | 13,165 | $492,766 | 140,769 |
| 2026-01-14 00:36 | 2026-01-12 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $37.43 | 20,533 | $768,550 | 154,514 |
| 2026-01-14 00:33 | 2026-01-12 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $37.43 | 27,289 | $1,021,427 | 579,394 |
| 2026-01-14 00:31 | 2026-01-12 | LQDA | Liquidia Corp | Boyle Dana | Officer | OPT+S | $37.43 | 11,047 | $413,489 | 156,700 |
| 2026-01-14 00:31 | 2026-01-12 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | OPT+S | $37.43 | 21,142 | $791,345 | 176,883 |
| 2026-01-14 01:37 | 2026-01-09 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $40.78 | 20,000 | $815,634 | 60,000 |
| 2026-01-14 00:34 | 2026-01-12 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $37.43 | 13,548 | $507,102 | 184,174 |
| 2026-01-14 00:34 | 2026-01-12 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $37.43 | 36,932 | $1,382,365 | 350,919 |
| 2026-01-14 04:43 | 2026-01-12 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | SELL | $32.14 | 10,758 | $345,723 | 8,638 |
| 2026-01-14 04:43 | 2026-01-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $32.56 | 8,518 | $277,339 | 61,804 |
| 2026-01-14 01:54 | 2026-01-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $27.99 | 48,300 | $1,351,762 | 215,011 |
| 2026-01-14 04:43 | 2026-01-12 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $32.62 | 16,236 | $529,639 | 639,151 |
| 2026-01-14 02:20 | 2026-01-09 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $17.00 | 588,235 | $9,999,995 | 1,853,488 |
| 2026-01-13 22:48 | 2026-01-13 | CLNN | Clene Inc. | MATLIN DAVID J | Director | BUY | $6.50 | 33,333 | $216,665 | 477,824 |
| 2026-01-14 00:33 | 2026-01-12 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | OPT+S | $37.43 | 66,610 | $2,493,212 | 1,037,528 |
| 2026-01-14 00:47 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Director | OPT+S | $551.24 | 280 | $154,348 | 187,164 |
| 2026-01-14 00:43 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Director | OPT+S | $522.39 | 24,520 | $12,808,956 | 187,164 |
| 2026-01-14 00:38 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | OPT+S | $550.33 | 240 | $132,080 | 455,589 |
| 2026-01-14 00:34 | 2026-01-09 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | OPT+S | $522.40 | 18,410 | $9,617,312 | 455,589 |
| 2026-01-14 00:03 | 2026-01-09 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | SELL | $186.19 | 1,887 | $351,341 | 84,907 |
| 2026-01-14 00:04 | 2026-01-12 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $169.00 | 19,215 | $3,247,348 | 306,891 |
| 2026-01-14 01:10 | 2026-01-12 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $479.51 | 22,500 | $10,788,876 | 0 |
| 2026-01-14 02:53 | 2026-01-09 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.16 | 213 | $8,554 | 38,659 |
| 2026-01-13 04:32 | 2026-01-12 | ZYME | Zymeworks Inc. | Moore Paul Andrew | Officer | OPT+S | $22.67 | 9,560 | $216,759 | 48,497 |
| 2026-01-12 16:44 | 2022-09-19 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $3.69 | 2,700 | $9,959 | 1,424,178 |
| 2026-01-13 05:59 | 2026-01-08 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% owner | BUY | $17.00 | 411,764 | $6,999,988 | 2,908,332 |
| 2026-01-13 00:38 | 2026-01-08 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.70 | 44,975 | $256,236 | 708,587 |
| 2026-01-13 05:58 | 2026-01-08 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% owner | BUY | $17.00 | 411,764 | $6,999,988 | 2,908,332 |
| 2026-01-13 01:10 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | Vida Ventures II, LLC | 10% owner | BUY | $18.00 | 835,000 | $15,030,000 | 157,387 |
| 2026-01-13 05:01 | 2026-01-08 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $75.54 | 80,000 | $6,043,168 | 4,518,447 |
| 2026-01-13 01:12 | 2026-01-08 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $26.23 | 132,500 | $3,476,018 | 765,188 |
| 2026-01-13 05:00 | 2026-01-12 | ZYME | Zymeworks Inc. | Smith Jeffrey T L | Officer | OPT+S | $22.67 | 9,310 | $211,090 | 26,708 |
| 2026-01-13 01:11 | 2026-01-08 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Director | SELL | $25.02 | 13,920 | $348,281 | 25,107 |
| 2026-01-13 05:58 | 2026-01-08 | ALMS | Alumis Inc. | Tananbaum James B. | Director, 10% owner | BUY | $17.00 | 411,764 | $6,999,988 | 2,908,332 |
| 2026-01-13 03:07 | 2026-01-12 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Director, Officer | OPT+S | $22.67 | 30,424 | $689,819 | 226,842 |
| 2026-01-13 04:28 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | EcoR1 Capital, LLC | Director | BUY | $18.00 | 2,222,222 | $39,999,996 | 347,305 |
| 2026-01-13 01:00 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | Kim Helen Susan | Director, 10% owner | BUY | $18.00 | 835,000 | $15,030,000 | 157,387 |
| 2026-01-13 00:21 | 2026-01-09 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $27.28 | 6,390 | $174,319 | 20,439 |
| 2026-01-13 01:09 | 2026-01-08 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.59 | 91,374 | $53,536 | 2,309,869 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $76.45 | 2,514 | $192,195 | 394,453 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Utter Christine Marie | Officer | SELL | $76.45 | 1,034 | $79,049 | 72,693 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Golden Lee Scott | Officer | SELL | $76.45 | 866 | $66,206 | 92,428 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | SELL | $77.06 | 6,347 | $489,081 | 111,312 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | SELL | $76.45 | 940 | $71,863 | 6,791 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | SELL | $77.02 | 7,348 | $565,946 | 80,141 |
| 2026-01-13 00:10 | 2026-01-08 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $1.82 | 1,281 | $2,336 | 1,035,925 |
| 2026-01-10 01:08 | 2026-01-07 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $85.08 | 44,199 | $3,760,579 | 17,494 |
| 2026-01-10 01:34 | 2026-01-08 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | Officer | SELL | $8.00 | 15,000 | $120,000 | 1,685,426 |
| 2026-01-10 00:05 | 2026-01-07 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $474.99 | 4,500 | $2,137,455 | 42,293 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.